SBECD is an anionic bcyclodextrin derivative with a sodium sulfonate salt separated from the hydrophobic cavity by a butyl spacer group. The substituent is introduced at positions 2, 3, and 6 in at least one of the glucopyranose units in the cyclodextrin structure. Introducing the sulfobutylether (SBE) into b-cyclodextrin can produce materials with different degrees of substitution, theoretically from 1 to 21; the hepta-substituted preparation (SBE7-b-CD) is the cyclodextrin with the most desirable drug carrier properties. sulfobutylether-β-cyclodextrin occurs as a white amorphous powder.
SBECD is an excipient mainly used in nitrogen-containing drugs. It has special affinity and inclusion properties for nitrogen-containing drugs.
SBE-β-CD is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.The amount of sulfobutylether-β-cyclodextrin that may be used is dependent on the purpose for inclusion in the formulation, the route of administration, and the ability of the cyclodextrin to complex with the drug being delivered.
SBECD is the sulfonated modified sodium salt of beta cyclodextrin,which is an anionic, highly water-soluble cyclodextrin derivative, can be well incorporated with drug molecules to form non-covalent complexes, thereby improving the stability, water solubility and safety of the drug , reducing nephrotoxicity, ease drug hemolysis, control drug release rate, mask bad odor, etc.
SBECD is derived from b-cyclodextrin, which is nephrotoxic when administered parenterally. However, studies have shown that sulfobutylether bcyclodextrin is well tolerated at high doses, when administered via intravenous bolus injections, orally, and by inhalation. Up to 9 g/day may be administered by IV infusion in a licensed voriconazole formulation. The safety following high doses of sulfobutylether-β-cyclodextrin intravenous administration in humans is continually being investigated.
SBECD has been subjected to an extensive battery of in vitro and in vivo genotoxicity and pharmacological evaluations. No genotoxic or mutagenic changes were observed with sulfobutylether β-cyclodextrin administration. sulfobutylether-β-cyclodextrin is biocompatible and exhibits no pharmacological activity. It is rapidly eliminated unmetabolized when administered intravenously.
Injection, oral, nasal, and eye, with special affinity and inclusion properties for nitrogen-containing drugs.
Please find attached TDS.
Normal package:10kg/fiber drum
SBECD is stable in the solid state and should be protected from high humidity. It should be stored in a tightly sealed container in a cool, dry place.
Injection or freeze-dried powder.
Voriconazole, caffezomib, sofibvir, ziprasidone mesylate, maropitam, aripiprazole, posaconazole,carbamazepine, L-phenylalanine nitrogen mustard.
We have a professional product research and development team,the most advanced production line and detecting instruments, sales team with humanistic service(including after-sale service).Conforms to GMP standand and meets USP42,EP10.
We have established a complete procedure to check products at all stages of the manufacturing process-raw materials, process materials, validated or tested materials finished goods etc..And,we have developed a procedure to identify the inspection and test status of all stages of the manufacturing process.We also keep samples for at least 2 years and keep doing stability test.
Our Minium Order Quantity is 1Kg, products can be sent within one week after payment confirmed.
We warmly welcome customers' audit,it's an effective way to build a better business relationship.